Roche Looks To Fuel Early-stage Partnerships In China While Shunning Branded Generics
This article was originally published in PharmAsia News
Executive Summary
SHANGHAI - Unlike many of its peers, Roche AG is not interested in developing a specific partnering strategy for China or other emerging markets, according to Joe McCracken, Roche's global head of business development and licensing. Instead, the Swiss pharma relies on a single global strategy that includes China as a key player, the exec told PharmAsia News Oct. 11 during an interview on the sidelines of the first BIO China conference in Shanghai